HopeStage
Back to all studies
CompletedNCT00811473

Quetiapine extended release for depression in young people with bipolarity

About this title

Pediatric Bipolar Depression

Read the official source — NCT00811473

Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.

Medication studyAges 10–17Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.

Listed locations
Dothan and 47 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2009
Recruitment status
Completed
Enrollment listed in the registry
193
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Colombia, India, ...
Age range
From 10 Years to 17 Years
Official registry ID
NCT00811473
Official title
Show the full official title

An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Dothan, United States · Scottsdale, United States · Little Rock, United States

45 more locations
  • Escondido, United States
  • Bradenton, United States
  • Gainsville, United States
  • North Miami, United States
  • Tampa, United States
  • Atlanta, United States
  • Smyrna, United States
  • Eagle, United States
  • Hoffman Estates, United States
  • Terre Haute, United States
  • Overland Park, United States
  • Wichita, United States
  • Clinton Township, United States
  • Minneapolis, United States
  • Flowood, United States
  • St Louis, United States
  • Lincoln, United States
  • Rochester, United States
  • Cincinnati, United States
  • Cleveland, United States
  • Mason, United States
  • Oklahoma City, United States
  • Charleston, United States
  • Memphis, United States
  • Wharton, United States
  • Virginia Beach, United States
  • Bothell, United States
  • Milwaukee, United States
  • Bogota D.c, Colombia
  • Bello, Colombia
  • Bogotá, Colombia
  • Medellín, Colombia
  • Vijaywada, India
  • Ahmedabad, India
  • Vadodara, India
  • Varanasi, India
  • León, Mexico
  • Monterrey, Mexico
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Pretoria, South Africa
  • Cape Town, South Africa
  • Taoyuan, Taiwan
  • Changhua, Taiwan
  • Taipei, Taiwan

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine XR and Placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies